{"status": "OK", "response": {"docs": [{"type_of_material": "News", "blog": [], "news_desk": "Magazine Desk", "lead_paragraph": "I. The Future Is Not the Present Three years ago, in a small conference room at the offices of the law firm Hogan & Hartson in Washington, I had the chance to talk with John G. Roberts Jr. At the time, Roberts was a lawyer in private practice, unsure whether Senate Democrats would hold a hearing on his nomination to be a federal appellate judge. (After being nominated three times, in 1992, 2001 and 2003, he would finally be given a hearing and confirmed in May 2003 after Republicans took control of the Senate.) In a conversation over cookies and coffee, Roberts spoke candidly about a wide range of topics, and I was impressed by his modesty, intelligence and sense of humor.", "headline": {"main": "Roberts V. The Future"}, "abstract": null, "print_page": "24", "word_count": 7308, "_id": "4fd24caf8eb7c8105d7ec76b", "snippet": "To learn about what kind of justice John G. Roberts Jr. might turn out to be, the Senate should ask the questions that will matter in 2015.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/08/28/magazine/28ROBERTS.html", "multimedia": [{"url": "imagepages/2005/08/26/magazine/28court.2.html", "rank": "2", "height": 325, "width": 250, "legacy": {"MultimediaPopupHeight2": "325", "MultimediaUrl2": "imagepages/2005/08/26/magazine/28court.2.html", "MultimediaPopupWidth2": "250", "MultimediaType2": "Image"}, "type": "Image"}, {"url": "imagepages/2005/08/26/magazine/28court.1.html", "rank": "1", "height": 325, "width": 250, "legacy": {"MultimediaPopupWidth1": "250", "MultimediaUrl1": "imagepages/2005/08/26/magazine/28court.1.html", "MultimediaPopupHeight1": "325", "MultimediaType1": "Image"}, "type": "Image"}, {"url": "imagepages/2005/08/26/magazine/28court.3.html", "rank": "3", "height": 325, "width": 250, "legacy": {"MultimediaPopupHeight3": "325", "MultimediaPopupWidth3": "250", "MultimediaUrl3": "imagepages/2005/08/26/magazine/28court.3.html", "MultimediaType3": "Image"}, "type": "Image"}], "subsection_name": null, "keywords": [{"name": "persons", "value": "ROBERTS, JOHN G JR"}, {"name": "organizations", "value": "SUPREME COURT"}, {"name": "subject", "value": "DECISIONS AND VERDICTS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Jeffrey", "rank": 1, "lastname": "Rosen"}], "original": "By Jeffrey Rosen"}, "document_type": "article", "pub_date": "2005-08-28T00:00:00Z", "section_name": "Magazine"}, {"type_of_material": "News", "blog": [], "news_desk": "Business/Financial Desk", "lead_paragraph": "Patients worldwide who suffered heart attacks or strokes while taking the painkiller Vioxx are preparing to sue its maker, Merck, exponentially increasing the company's potential liability. Last week, a jury in Texas found Merck liable in the death of Robert C. Ernst and voted to award $253.5 million to his widow, Carol. Jurors said they concluded that Merck was long aware of Vioxx's potential heart risks but concealed them.", "headline": {"main": "For Merck, Global Legal Woes"}, "abstract": "Patients worldwide who suffered heart attacks or strokes while taking painkiller Vioxx are preparing to sue its maker, Merck; about 4,000 lawsuits are pending in US, but there are potentially many more around world, especially in Europe, where Vioxx, used to relieve pain of arthritis, was extremely popular (M)", "print_page": "14", "word_count": 470, "_id": "4fd2487e8eb7c8105d7e5661", "snippet": "International Herald Tribune.", "source": "International Herald Tribune", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/08/26/business/26merck.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "glocations", "value": "EUROPE"}, {"name": "organizations", "value": "MERCK & CO INC"}, {"name": "organizations", "value": "MERCK & COMPANY INCORPORATED"}, {"name": "subject", "value": "HEART"}, {"name": "subject", "value": "STROKE"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}, {"name": "subject", "value": "SUITS AND LITIGATION"}, {"name": "subject", "value": "MEDICINE AND HEALTH"}, {"name": "subject", "value": "VIOXX (DRUG)"}, {"name": "subject", "value": "LIABILITY FOR PRODUCTS"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Elisabeth", "rank": 1, "lastname": "ROSENTHAL"}], "original": "By ELISABETH ROSENTHAL"}, "document_type": "article", "pub_date": "2005-08-26T00:00:00Z", "section_name": "Health; Business"}, {"type_of_material": "News", "blog": [], "news_desk": "National Desk", "lead_paragraph": "After accusations that some government scientists used their official positions for private gain, the National Institutes of Health announced rules on Thursday that ban its scientists from consulting for drug companies. ''Our research should be based on scientific evidence that is not influenced by any other factors,'' Dr. Elias A. Zerhouni, director of the health institutes, said at a news conference.", "headline": {"main": "Health Agency Tightens Rules Governing Federal Scientists"}, "abstract": null, "print_page": "13", "word_count": 839, "_id": "4fd25f7a8eb7c8105d80ef79", "snippet": "The National Institutes of Health announced rules that ban scientists from consulting for drug companies.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/2005/08/26/politics/26rules.html", "multimedia": [], "subsection_name": null, "keywords": [{"name": "organizations", "value": "NATIONAL INSTITUTES OF HEALTH"}, {"name": "subject", "value": "DRUGS (PHARMACEUTICALS)"}], "byline": {"person": [{"organization": "", "role": "reported", "firstname": "Gardiner", "rank": 1, "lastname": "HARRIS"}], "original": "By GARDINER HARRIS"}, "document_type": "article", "pub_date": "2005-08-26T00:00:00Z", "section_name": "Health; U.S."}], "meta": {"hits": 3, "offset": 0, "time": 263}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}